PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8720036-4 1995 (2) ANP infusion significantly increased urine flow rate (UFR), creatinine clearance (CCr), fractional excretion rates of sodium (FENa) and chloride (FECl), and urinary phosphorus and magnesium (Mg) excretions in a dose-dependent manner without affecting renal plasma flow and fractional excretion rates of potassium and urea in cisplatin-treated rats. Potassium 307-316 natriuretic peptide A Rattus norvegicus 4-7 10382996-5 1999 RESULTS: A single systemic injection of Ad.RSV-ANP at a dose of 1.2x10(10) pfu results in a significant increase in urine excretion, water intake, urinary sodium and potassium excretion. Potassium 166-175 natriuretic peptide A Rattus norvegicus 47-50 8884981-3 1996 Results showed that in the submaxillary gland, ANF increased sodium and decreased potassium excretion when salivation was stimulated by methacholine (MC) or substance P (SP). Potassium 82-91 natriuretic peptide A Rattus norvegicus 47-50 8884981-5 1996 On the other hand, in the parotid gland, ANF increased both sodium and potassium excretion when salivation was induced either by MC or SP but did not modify electrolyte output in MX induced salivary secretion. Potassium 71-80 natriuretic peptide A Rattus norvegicus 41-44 8886404-16 1996 The TAPP-induced diuretic action, increased sodium/potassium excretion and elevated urinary cyclic GMP levels were also reversed by anti-ANF antibodies. Potassium 51-60 natriuretic peptide A Rattus norvegicus 137-140 11473634-13 2001 Solute clearances (+175% for sodium and +26% for potassium) were significantly increased in the H-ANP group, mainly as a result of the increased fluid removal in this group. Potassium 49-58 natriuretic peptide A Rattus norvegicus 98-101 7904926-2 1993 Atrial natriuretic factor effects on neuronal noradrenaline release evoked by angiotensin II or III and high potassium solution plus angiotensin II and III in the rat hypothalamus were studied. Potassium 109-118 natriuretic peptide A Rattus norvegicus 0-25 7900841-2 1995 Infusions of ANF caused a significantly greater increase in urinary excretion of fluid, sodium, and potassium in virgin than in pregnant (13-15 days and 21 days) rats. Potassium 100-109 natriuretic peptide A Rattus norvegicus 13-16 7915002-5 1994 ANF produced a significantly greater suppression of potassium-induced aldosterone secretion in cells from OVX estradiol-treated rats than in cells from OVX progesterone-treated animals. Potassium 52-61 natriuretic peptide A Rattus norvegicus 0-3 8402382-9 1993 Furthermore, atrial natriuretic factor (10 nM) also reduced high potassium solution evoked secretion of norepinephrine. Potassium 65-74 natriuretic peptide A Rattus norvegicus 13-38 1679107-3 1991 Both doses (0.1 and 0.3 microgram/minutes/kg) of ANF administered produced a marked increase in urinary flow, sodium and potassium excretion in the SL rats. Potassium 121-130 natriuretic peptide A Rattus norvegicus 49-52 8441823-5 1993 Results showed that ANF decreased bile flow and the excretion rate of sodium, potassium, chloride, bile acids, cholesterol and proteins. Potassium 78-87 natriuretic peptide A Rattus norvegicus 20-23 1531208-3 1992 In the rat, intraperitoneal injections of pepsanurin (0.5 ml/100 g body wt) significantly inhibited the effects of an intravenous bolus of atrial natriuretic peptide (ANP) (0.5 micrograms) on water, sodium, and potassium excretion without altering systemic blood pressure. Potassium 211-220 natriuretic peptide A Rattus norvegicus 139-165 1832749-4 1991 The icv administration of the h-ANP antiserum significantly increased the spontaneous water intake, urine output and urinary potassium excretion in rats given water ad libitum. Potassium 125-134 natriuretic peptide A Rattus norvegicus 32-35 19215353-6 1990 The ability of potassium and glutamate to cause a mean 50% increase of ANP secretion above baseline was abolished after deleting calcium chloride from the medium. Potassium 15-24 natriuretic peptide A Rattus norvegicus 71-74 1699751-5 1990 Furthermore, our data suggest that the form of ANP released from these cultures, following either forskolin treatment alone or forskolin treatment followed by acute high potassium depolarisation, was atriopeptin III (ANP5-28). Potassium 170-179 natriuretic peptide A Rattus norvegicus 47-50 2143001-1 1990 The effects of intraventricularly administered atrial natriuretic peptide (ANP) on the brain water, sodium, and potassium contents in ischemic brain edema were investigated. Potassium 112-121 natriuretic peptide A Rattus norvegicus 75-78 2140017-7 1990 ProANF-(1-30), (79-98), and ANF significantly (P less than 0.05) increased urinary potassium excretion. Potassium 83-92 natriuretic peptide A Rattus norvegicus 3-6 2527408-8 1989 In vivo study showed that ANP was released from the rat spinal cord by depolarizing concentration of potassium. Potassium 101-110 natriuretic peptide A Rattus norvegicus 26-29 2138899-7 1990 After ANP infusion there was a prompt restoration of GFR, with a large rise in urine, sodium and potassium excretion rates. Potassium 97-106 natriuretic peptide A Rattus norvegicus 6-9 2532482-0 1989 Aldosterone and renin inhibition by atrial natriuretic factor in potassium-loaded rats. Potassium 65-74 natriuretic peptide A Rattus norvegicus 36-61 2532482-4 1989 Infusion of ANF at 45 ng.kg-1.min-1 in potassium-loaded rats lowered aldosterone secretion to 1.32 +/- 0.21 ng/min (P less than 0.05) but did not significantly reduce PRA (11 +/- 2 ng ANG I.ml-1.h-1 (P greater than 0.05). Potassium 39-48 natriuretic peptide A Rattus norvegicus 12-15 2532482-8 1989 These results indicate that ANF can inhibit chronic potassium-stimulated aldosterone secretion in the rat independently of its inhibitory actions on renin release. Potassium 52-61 natriuretic peptide A Rattus norvegicus 28-31 19210391-2 1990 The facts that immunoreactive ANF (ir-ANF) is also present in nerve terminals in the external layer of the median eminence (ME) (5), ir-ANF can be released from the hypothalamus in vitro by potassium depolarization (6) and specific ANF binding sites are present at a high concentration in rat pituitary tissue (7) suggest that ANF may be involved in hypothalamic-pituitary regulation. Potassium 190-199 natriuretic peptide A Rattus norvegicus 30-33 19210391-2 1990 The facts that immunoreactive ANF (ir-ANF) is also present in nerve terminals in the external layer of the median eminence (ME) (5), ir-ANF can be released from the hypothalamus in vitro by potassium depolarization (6) and specific ANF binding sites are present at a high concentration in rat pituitary tissue (7) suggest that ANF may be involved in hypothalamic-pituitary regulation. Potassium 190-199 natriuretic peptide A Rattus norvegicus 38-41 19210391-2 1990 The facts that immunoreactive ANF (ir-ANF) is also present in nerve terminals in the external layer of the median eminence (ME) (5), ir-ANF can be released from the hypothalamus in vitro by potassium depolarization (6) and specific ANF binding sites are present at a high concentration in rat pituitary tissue (7) suggest that ANF may be involved in hypothalamic-pituitary regulation. Potassium 190-199 natriuretic peptide A Rattus norvegicus 38-41 19210391-2 1990 The facts that immunoreactive ANF (ir-ANF) is also present in nerve terminals in the external layer of the median eminence (ME) (5), ir-ANF can be released from the hypothalamus in vitro by potassium depolarization (6) and specific ANF binding sites are present at a high concentration in rat pituitary tissue (7) suggest that ANF may be involved in hypothalamic-pituitary regulation. Potassium 190-199 natriuretic peptide A Rattus norvegicus 38-41 19210391-2 1990 The facts that immunoreactive ANF (ir-ANF) is also present in nerve terminals in the external layer of the median eminence (ME) (5), ir-ANF can be released from the hypothalamus in vitro by potassium depolarization (6) and specific ANF binding sites are present at a high concentration in rat pituitary tissue (7) suggest that ANF may be involved in hypothalamic-pituitary regulation. Potassium 190-199 natriuretic peptide A Rattus norvegicus 38-41 2151009-1 1990 We investigated the effect of intraventricularly administered atrial natriuretic peptide (ANP) on the brain water, sodium and potassium contents in ischaemic brain oedema. Potassium 126-135 natriuretic peptide A Rattus norvegicus 62-88 2968238-2 1988 In the present study, we observed rat alpha ANP to inhibit aldosterone secretion stimulated by 10 mM potassium with an IC50 of 0.15 +/- 0.02 nM (mean +/- SE) in dispersed rat adrenal glomerulosa cells. Potassium 101-110 natriuretic peptide A Rattus norvegicus 44-47 2968238-6 1988 When this same ANP-containing superfusate was incubated with dispersed adrenal glomerulosa cells, potassium-stimulated aldosterone secretion was inhibited by 90%, proving sustained biological potency of the superfused ANP. Potassium 98-107 natriuretic peptide A Rattus norvegicus 15-18 2968238-6 1988 When this same ANP-containing superfusate was incubated with dispersed adrenal glomerulosa cells, potassium-stimulated aldosterone secretion was inhibited by 90%, proving sustained biological potency of the superfused ANP. Potassium 98-107 natriuretic peptide A Rattus norvegicus 218-221 2965959-3 1988 In 13 (87%) of 15 SFO neurons, ANP at 10(-7) M depressed by more than 40% the excitation induced by AII at 10(-7) M, while ANP did not always depress the excitation induced by raising the extracellular potassium concentrations in 6 SFO cells tested. Potassium 202-211 natriuretic peptide A Rattus norvegicus 31-34 2961879-5 1987 ANP treatment resulted in a significant peak increase in sodium (5.6-fold), lithium (2.1-fold), potassium (2.3-fold) and water (5.1-fold) excretion. Potassium 96-105 natriuretic peptide A Rattus norvegicus 0-3 2942746-0 1986 Effect of atrial natriuretic factor on the plasma aldosterone response to potassium infusion in rats--in vivo study. Potassium 74-83 natriuretic peptide A Rattus norvegicus 10-35 2948755-1 1987 Previous studies have shown that atrial natriuretic peptide (ANP) inhibits the secretion of aldosterone by isolated adrenal glomerulosa cells stimulated by angiotensin II, adrenocorticotropic hormone and potassium in vitro. Potassium 204-213 natriuretic peptide A Rattus norvegicus 33-59 2948755-1 1987 Previous studies have shown that atrial natriuretic peptide (ANP) inhibits the secretion of aldosterone by isolated adrenal glomerulosa cells stimulated by angiotensin II, adrenocorticotropic hormone and potassium in vitro. Potassium 204-213 natriuretic peptide A Rattus norvegicus 61-64 3008159-1 1986 Previous studies have shown that atrial natriuretic peptide (ANP) inhibits the secretion of aldosterone by isolated adrenal glomerulosa cells stimulated by angiotensin II, ACTH and potassium in vitro and by angiotensin II in conscious unrestrained rats. Potassium 181-190 natriuretic peptide A Rattus norvegicus 33-59 6092045-3 1984 ANF inhibited aldosterone secretion stimulated by 10(-8)M angiotensin II with an IC50 of 1.3 X 10(-9)M. Aldosterone secretion stimulated by 2.9 X 10(-10)M ACTH and by 15 mM potassium was similarly inhibited by ANF. Potassium 173-182 natriuretic peptide A Rattus norvegicus 0-3 2948068-2 1986 After determination of basal renal function, ANF at different doses induced a dose dependent increase of glomerular filtration rate (GFR), diuresis (V), sodium (UNaV) and potassium (UKV) excretion. Potassium 171-180 natriuretic peptide A Rattus norvegicus 45-48 2985222-2 1985 In the absence of CEI, ANF produced rapid and significant increases in sodium, potassium, calcium, and urine excretions while blood pressure declined transiently. Potassium 79-88 natriuretic peptide A Rattus norvegicus 23-26 2981380-2 1985 The results proved conclusively that ANF acted directly on the kidney since urine volume and fractional excretion of sodium, potassium, chloride and calcium were elevated in a dose-related manner in the ANF-treated kidney, but were not significantly affected in the contralateral saline-infused organ. Potassium 125-134 natriuretic peptide A Rattus norvegicus 37-40 2981380-2 1985 The results proved conclusively that ANF acted directly on the kidney since urine volume and fractional excretion of sodium, potassium, chloride and calcium were elevated in a dose-related manner in the ANF-treated kidney, but were not significantly affected in the contralateral saline-infused organ. Potassium 125-134 natriuretic peptide A Rattus norvegicus 203-206 2940098-4 1986 ANF was found to be released from rat hypothalamus by a depolarizing concentration of potassium and by a calcium-dependent mechanism. Potassium 86-95 natriuretic peptide A Rattus norvegicus 0-3 2946967-9 1986 In addition, a tremendous rise in fractional excretion rates of sodium and potassium after administration of ANF was observed. Potassium 75-84 natriuretic peptide A Rattus norvegicus 109-112 2931997-9 1985 Furthermore, our data suggest that ANF increases potassium excretion only if it increases GFR. Potassium 49-58 natriuretic peptide A Rattus norvegicus 35-38 2985222-3 1985 In the presence of CEI, ANF enhanced the excretion of sodium and potassium but not of calcium and urine. Potassium 65-74 natriuretic peptide A Rattus norvegicus 24-27 6539299-0 1984 Atrial natriuretic factor inhibits angiotensin-, norepinephrine-, and potassium-induced vascular contractility. Potassium 70-79 natriuretic peptide A Rattus norvegicus 0-25